KOOL Profile
Cesca
Therapeutics Inc. (KOOL) is a California-based medical technology
company that focuses on developing and commercializing innovative
cell-based therapeutics. The company is engaged in the research,
development, and marketing of medical devices and therapies that
enable the collection, separation, storage, and delivery of cell-based
therapies. Cesca has a portfolio of proprietary products and
technologies that are designed to address the needs of the
regenerative medicine and cell therapy markets.
Cesca's
proprietary technologies include its AXP AutoXpress Platform, which
is a fully automated, closed system for the rapid, efficient, and
reliable processing of cell-based therapies. The AXP system is used
for the collection, separation, and preservation of stem cells and
other cells that are used in various cell-based therapies. The
company's other proprietary technologies include the MarrowXpress
(MXP) platform, which is used to concentrate stem cells from bone
marrow, and the PXP system, which is used for the isolation and
purification of platelets.
Cesca's products and technologies
are used in various therapeutic areas, including orthopedics, vascular
medicine, neurology, and oncology. The company's products and
technologies are used by hospitals, clinics, and research institutions
worldwide.
In addition to its product portfolio, Cesca has a
strong intellectual property portfolio, with over 100 issued and
pending patents. The company's patents cover various aspects of its
technologies, including the AXP system, the MXP system, and the PXP
system.
Cesca was founded in 1986 and went public in 2004. The
company is listed on the NASDAQ exchange under the ticker symbol
&";
|
